Asset profile
Semzuvolimab
Monoclonal antibody
Evidence outlook · registrational
HIV: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT03743376: The study randomized 31 participants to two semzuvolimab dosing schedules or standard antiretroviral therapy, but it was open-label rather than blinded. Its primary safety endpoint was a clinical adverse-event measure, although the comparison cannot be judged because results are not posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.